Literature DB >> 34767437

Taking a BiTE Out of CAR-T Cell Efficacy.

Haley M Newman1, David T Teachey1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34767437      PMCID： PMC8937006          DOI： 10.1200/JCO.21.02465

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.

Authors:  Ahmad Rayes; Richard L McMasters; Maureen M O'Brien
Journal:  Pediatr Blood Cancer       Date:  2016-02-23       Impact factor: 3.167

2.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Authors:  Rebecca Gardner; David Wu; Sindhu Cherian; Min Fang; Laïla-Aïcha Hanafi; Olivia Finney; Hannah Smithers; Michael C Jensen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

3.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

4.  Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.

Authors:  Regina M Myers; Agne Taraseviciute; Seth M Steinberg; Adam J Lamble; Jennifer Sheppard; Bonnie Yates; Alexandra E Kovach; Brent Wood; Michael J Borowitz; Maryalice Stetler-Stevenson; Constance M Yuan; Vinodh Pillai; Toni Foley; Perry Chung; Lee Chen; Daniel W Lee; Colleen Annesley; Amanda DiNofia; Stephan A Grupp; Samuel John; Deepa Bhojwani; Patrick A Brown; Theodore W Laetsch; Lia Gore; Rebecca A Gardner; Susan R Rheingold; Michael A Pulsipher; Nirali N Shah
Journal:  J Clin Oncol       Date:  2021-11-12       Impact factor: 44.544

5.  Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.

Authors:  Marie-Emilie Dourthe; Florence Rabian; Nicolas Boissel; André Baruchel; Karima Yakouben; Florian Chevillon; Aurélie Cabannes-Hamy; Françoise Méchinaud; Audrey Grain; Delphine Chaillou; Ilhem Rahal; Sophie Caillat-Zucman; Emmanuelle Lesprit; Jérôme Naudin; Julie Roupret-Serzec; Nathalie Parquet; Anne Brignier; Valérie Guérin-El Khourouj; Elodie Lainey; Aurélie Caye-Eude; Hélène Cavé; Emmanuelle Clappier; Stéphanie Mathis; Elie Azoulay; Jean Hugues Dalle; Nathalie Dhédin; Isabelle Madelaine; Jérôme Larghero
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

6.  Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.

Authors:  Stephan Kadauke; Regina M Myers; Yimei Li; Richard Aplenc; Diane Baniewicz; David M Barrett; Allison Barz Leahy; Colleen Callahan; Joseph G Dolan; Julie C Fitzgerald; Whitney Gladney; Simon F Lacey; Hongyan Liu; Shannon L Maude; Regina McGuire; Laura S Motley; David T Teachey; Gerald B Wertheim; Lisa Wray; Amanda M DiNofia; Stephan A Grupp
Journal:  J Clin Oncol       Date:  2021-01-08       Impact factor: 44.544

Review 7.  Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies.

Authors:  Jiali Cheng; Lei Zhao; Yuanyuan Zhang; Yun Qin; Yuqi Guan; Tong Zhang; Chaohong Liu; Jianfeng Zhou
Journal:  Front Oncol       Date:  2019-11-21       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.